Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Other Accumulated Expenses (2022 - 2025)

Historic Other Accumulated Expenses for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $4.6 million.

  • Atara Biotherapeutics' Other Accumulated Expenses fell 8033.75% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year decrease of 8033.75%. This contributed to the annual value of $20.2 million for FY2024, which is 3665.56% down from last year.
  • As of Q3 2025, Atara Biotherapeutics' Other Accumulated Expenses stood at $4.6 million, which was down 8033.75% from $7.7 million recorded in Q2 2025.
  • Atara Biotherapeutics' Other Accumulated Expenses' 5-year high stood at $33.0 million during Q1 2024, with a 5-year trough of $4.6 million in Q3 2025.
  • In the last 4 years, Atara Biotherapeutics' Other Accumulated Expenses had a median value of $23.8 million in 2023 and averaged $21.7 million.
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first surged by 6987.85% in 2023, then plummeted by 8033.75% in 2025.
  • Atara Biotherapeutics' Other Accumulated Expenses (Quarter) stood at $25.0 million in 2022, then grew by 27.34% to $31.8 million in 2023, then crashed by 36.66% to $20.2 million in 2024, then crashed by 76.94% to $4.6 million in 2025.
  • Its last three reported values are $4.6 million in Q3 2025, $7.7 million for Q2 2025, and $24.1 million during Q1 2025.